Kevin D. Freeman - SEC Form 4 Insider Trading Activity

Summary

Updated Aug 4, 2026

Kevin D. Freeman is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $73K. Historical track record: 4/5 stars across 6 tracked purchases.

Profile

Kevin D. Freeman is a corporate insider at GALECTIN THERAPEUTICS INC (GALT). Freeman has reported 7 insider filings with the SEC since 2024. The most recent filing was in January 2026.

RoleInsider
Notability20/100

Board memberships

Track Record

InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.

InsiderAlpha rating★★★★☆ (4/5)
Total purchases tracked6
Purchases with forward-return data6
30-day win rate83%
90-day win rate33%
Avg 5-day return+5.10%
Avg 30-day return+13.59%
Avg 90-day return-2.81%
Best 30-day return+46.32%

Trading Pattern

InsiderAlpha's records for Kevin D. Freeman go back to 2024: 6 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $12K (6 buys totaling $73K). The largest single buy on record is $20K of GALT in 2025. 1 recorded transaction carries a Rule 10b5-1 flag, meaning it was pre-scheduled under a written trading plan rather than discretionary.

Career & Filing History

Every role Kevin D. Freeman has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2025-12-23GALTGALECTIN THERAPEUTICS INCP - Open-market purchase [10b5-1]5.5K$3.55$20K
2025-07-18GALTGALECTIN THERAPEUTICS INCP - Open-market purchase5.0K$2.90$14K
2024-12-26GALTGALECTIN THERAPEUTICS INCP - Open-market purchase10.0K$0.81$8K
2024-10-17GALTGALECTIN THERAPEUTICS INCP - Open-market purchase1.3K$2.64$3K
2024-10-16GALTGALECTIN THERAPEUTICS INCP - Open-market purchase5.0K$2.70$14K
2024-10-16GALTGALECTIN THERAPEUTICS INCP - Open-market purchase5.0K$2.70$14K

Most Active Insiders Right Now

Kevin D. Freeman has no recent co-filers at the same companies, so here are the insiders with the largest open-market activity across the market in the last 90 days.

More Notable Insiders

Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:

Frequently Asked Questions

Who is Kevin D. Freeman?

Kevin D. Freeman is a corporate insider at GALECTIN THERAPEUTICS INC (GALT). Freeman has reported 7 insider filings with the SEC since 2024. The most recent filing was in January 2026.…

Has Kevin D. Freeman been buying or selling stock?

Recorded transactions: 6 open-market purchases ($73K) and 0 open-market sales across all tracked filings.

How accurate is Kevin D. Freeman's historical track record?

Across 6 tracked purchases, Kevin D. Freeman averaged +13.6% avg 30-day return with a 83% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.

Where can I see all of Kevin D. Freeman's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Kevin D. Freeman profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.